In today’s session Valeant Pharmaceuticals Intl Inc (VRX) registered an unusually high (279) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2018 call, expecting serious VRX increase. With 279 contracts traded and 17734 open interest for the Jan, 18 contract, it seems this is a quite bullish bet. The option with symbol: VRX180119C00027500 closed last at: $3.35 or 4.3% down. About 5.08 million shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 46.07% since April 18, 2016 and is downtrending. It has underperformed by 50.50% the S&P500.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage
Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 rate it a “Buy”, 2 “Sell”, while 13 “Hold”. This means 35% are positive. Valeant Pharmaceuticals Intl has been the topic of 79 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, March 16. The company was initiated on Friday, October 9 by Mizuho. Morgan Stanley maintained it with “Equal-Weight” rating and $98.0 target price in Tuesday, November 17 report. The company was initiated on Friday, February 19 by Wells Fargo. The rating was maintained by Jefferies on Wednesday, June 8 with “Buy”. The firm earned “Hold” rating on Wednesday, March 16 by Canaccord Genuity. The stock has “Equal-Weight” rating given by Morgan Stanley on Friday, October 2. The company was downgraded on Wednesday, March 16 by Nomura. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Buy” rating by Rodman & Renshaw on Tuesday, August 9. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Wednesday, November 11 with “Outperform” rating.
According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”
Insitutional Activity: The institutional sentiment increased to 0.88 in Q2 2016. Its up 0.02, from 0.86 in 2016Q1. The ratio improved, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Moreover, Glg Prns L P has 0.21% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 350,000 shares. Okumus Fund Mgmt Ltd last reported 14.79% of its portfolio in the stock. Fifth Third National Bank reported 231 shares or 0% of all its holdings. Moreover, Endurance Wealth Management Inc has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 375 shares. Dekabank Deutsche Girozentrale reported 3,503 shares or 0% of all its holdings. Bank & Trust Of America De, a North Carolina-based fund reported 3.83 million shares. Acadian Asset Limited Company accumulated 186,884 shares or 0.02% of the stock. State Of New Jersey Common Pension Fund D owns 20,000 shares or 0% of their US portfolio. Cohen Klingenstein Ltd Liability accumulated 0.06% or 16,738 shares. Anchorage Cap Gru Ltd Liability Com has 0.24% invested in the company for 498,700 shares. Ontario Teachers Pension Plan Board holds 0.01% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 26,460 shares. Stanley Capital Management Limited has 1.17% invested in the company for 57,800 shares. Pentwater Management L P owns 3.90M shares or 1.05% of their US portfolio. Mackenzie Fin Corporation accumulated 872,841 shares or 0.1% of the stock. Meag Munich Ergo Kapitalanlagegesellschaft Mbh accumulated 55,000 shares or 0.1% of the stock.
Insider Transactions: Since June 9, 2016, the stock had 2 insider purchases, and 0 sales for $5.04 million net activity. $4.94 million worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was bought by PAPA JOSEPH C. On Thursday, August 11 the insider KARABELAS ARGERIS N bought $98,600.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $6.28 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.
VRX Company Profile
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Investorplace.com which released: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” on November 15, 2016, also Fool.ca with their article: “Valeant Pharmaceuticals Intl Inc.: Has This Stock Finally Hit Bottom?” published on November 18, 2016, Bloomberg.com published: “Valeant Plunges Again, Warning ‘Could Still Be Surprises'” on November 08, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Profitconfidential.com and their article: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” published on November 10, 2016 as well as Profitconfidential.com‘s news article titled: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” with publication date: November 03, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.